Phase II Safety and Efficacy Study of Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Metastatic or Unresectable Sarcomatoid Renal Cell Carcinoma.

Trial Profile

Phase II Safety and Efficacy Study of Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Metastatic or Unresectable Sarcomatoid Renal Cell Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Gemcitabine (Primary) ; Capecitabine
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 May 2016 Status changed from active, no longer recruiting to completed.
    • 25 Jun 2015 According to the ClinicalTrials.gov record, planned end date changed to 1 Aug 2017.
    • 25 Jun 2015 According to the ClinicalTrials.gov record, planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top